Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Cell Research)
Source: Cell Research - April 17, 2024 Category: Cytology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Cancer Control)
Source: Cancer Control - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Impact of immune ‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
ConclusionsThe results of this study show that immune-related adverse events are associated with improved survival outcomes in patients with extensive-stage small cell lung cancer. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Tadashi Nishimura,
Hajime Fujimoto,
Takumi Fujiwara,
Kentaro Ito,
Atsushi Fujiwara,
Hisamichi Yuda,
Hidetoshi Itani,
Masahiro Naito,
Shuji Kodama,
Kazuki Furuhashi,
Akihiko Yagi,
Haruko Saiki,
Taro Yasuma,
Tomohito Okano,
Atsushi Tomaru,
Mo Tags: RESEARCH ARTICLE Source Type: research
Application Value of CYFRA21-1 Combined with NSE, CEA, and SCC-Ag in Lung Cancer
CONCLUSIONS: The combined assay of CYFRA21-1, NSE, and CEA addresses the aspects of accuracy, sensitivity, specificity, and economic cost and should be considered as a potential diagnostic test in LC.PMID:38623667 | DOI:10.7754/Clin.Lab.2023.230662 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Yuping Fu Dandan Li Ya Zhu Sha Yan Xia Wang Zhenshuai Lian Qi Xie Zhi'an He Source Type: research
Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer
We describe the effectiveness of continuous ICIs beyond progression in SCLC. Medical courses of SCLC patients treated with chemo-immunotherapy were retrospectively reviewed at our hospital. The study included 36 patients with a median age of 73 years (range 46-83 years) who introduced chemo-immunotherapy between September 2019 and December 2022. Atezolizumab and durvalumab in combination with platinum plus etoposide were administered in 24 and 12 patients, respectively. The overall response rate was 67% and the disease control rate was 86%. The median progression-free survival and time to treatment failure (TTF) were 5.1 a...
Source: Cancer Control - April 16, 2024 Category: Cancer & Oncology Authors: Ken Yamamoto Taira Ninomaru Hideaki Okada Katsuya Hirano Temiko Shimada Akito Hata Source Type: research
Application Value of CYFRA21-1 Combined with NSE, CEA, and SCC-Ag in Lung Cancer
CONCLUSIONS: The combined assay of CYFRA21-1, NSE, and CEA addresses the aspects of accuracy, sensitivity, specificity, and economic cost and should be considered as a potential diagnostic test in LC.PMID:38623667 | DOI:10.7754/Clin.Lab.2023.230662 (Source: Cancer Control)
Source: Cancer Control - April 16, 2024 Category: Cancer & Oncology Authors: Yuping Fu Dandan Li Ya Zhu Sha Yan Xia Wang Zhenshuai Lian Qi Xie Zhi'an He Source Type: research
Application Value of CYFRA21-1 Combined with NSE, CEA, and SCC-Ag in Lung Cancer
CONCLUSIONS: The combined assay of CYFRA21-1, NSE, and CEA addresses the aspects of accuracy, sensitivity, specificity, and economic cost and should be considered as a potential diagnostic test in LC.PMID:38623667 | DOI:10.7754/Clin.Lab.2023.230662 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Yuping Fu Dandan Li Ya Zhu Sha Yan Xia Wang Zhenshuai Lian Qi Xie Zhi'an He Source Type: research
